These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30736159)

  • 21. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
    Tchang BG; Shukla AP; Aronne LJ
    Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
    Brown RJ; Oral EA; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Gorden P
    Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature.
    Misra A; Garg A
    Medicine (Baltimore); 2003 Mar; 82(2):129-46. PubMed ID: 12640189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.
    Simha V; Subramanyam L; Szczepaniak L; Quittner C; Adams-Huet B; Snell P; Garg A
    J Clin Endocrinol Metab; 2012 Mar; 97(3):785-92. PubMed ID: 22170723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function.
    Bruder-Nascimento T; Kress TC; Belin de Chantemele EJ
    F1000Res; 2019; 8():. PubMed ID: 31656583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.
    Ajluni N; Dar M; Xu J; Neidert AH; Oral EA
    J Diabetes Metab; 2016 Mar; 7(3):. PubMed ID: 27642538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on Therapeutic Options in Lipodystrophy.
    Akinci B; Meral R; Oral EA
    Curr Diab Rep; 2018 Oct; 18(12):139. PubMed ID: 30370487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance.
    Lambadiari V; Kountouri A; Maratou E; Liatis S; Dimitriadis GD; Karpe F
    Front Endocrinol (Lausanne); 2021; 12():684182. PubMed ID: 34168618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lipodystrophy. Mechanisms, clinical presentation, therapy].
    Miehle K; Stumvoll M; Fasshauer M
    Internist (Berl); 2011 Apr; 52(4):362, 364-6, 368-70 passim. PubMed ID: 21424143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metreleptin treatment of non-HIV lipodystrophy syndromes.
    Chevalier B; Lemaitre M; Leguier L; Mapihan KL; Douillard C; Jannin A; Espiard S; Vantyghem MC
    Presse Med; 2021 Nov; 50(3):104070. PubMed ID: 34571177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.
    Lebastchi J; Ajluni N; Neidert A; Oral EA
    J Clin Endocrinol Metab; 2015 Nov; 100(11):3967-70. PubMed ID: 26390101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leptin in congenital and HIV-associated lipodystrophy.
    Tsoukas MA; Farr OM; Mantzoros CS
    Metabolism; 2015 Jan; 64(1):47-59. PubMed ID: 25267014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipodystrophies in Children.
    Mainieri F; Chiarelli F
    Horm Res Paediatr; 2022; 95(4):305-320. PubMed ID: 35189617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
    Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
    J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipodystrophies in non-insulin-dependent children: Treatment options and results from recombinant human leptin therapy.
    Calcaterra V; Magenes VC; Rossi V; Fabiano V; Mameli C; Zuccotti G
    Pharmacol Res; 2023 Jan; 187():106629. PubMed ID: 36566927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
    Nguyen ML; Sachdev V; Burklow TR; Li W; Startzell M; Auh S; Brown RJ
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4327-e4339. PubMed ID: 34223895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of diet and body weight in treatment-resistant acquired partial lipodystrophy after hematopoietic stem cell transplantation and its potential for metabolic improvement.
    Ishida E; Horiguchi K; Matsumoto S; Ozawa A; Sekiguchi S; Yamada E
    Diabetol Int; 2024 Apr; 15(2):290-296. PubMed ID: 38524924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities.
    Akinci B; Koseoglu FD; Onay H; Yavuz S; Altay C; Simsir IY; Ozisik S; Demir L; Korkut M; Yilmaz N; Ozen S; Akinci G; Atik T; Calan M; Secil M; Comlekci A; Demir T
    Metabolism; 2015 Sep; 64(9):1086-95. PubMed ID: 26139569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipodystrophy Syndromes.
    Hussain I; Garg A
    Endocrinol Metab Clin North Am; 2016 Dec; 45(4):783-797. PubMed ID: 27823605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipodystrophy: lessons in lipid and energy metabolism.
    Simha V; Garg A
    Curr Opin Lipidol; 2006 Apr; 17(2):162-9. PubMed ID: 16531753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.